SHINKEI Therapeutics, Inc
1 clinical trials · Sponsor
◉ Watch SHINKEI Therapeutics, Inc
| Record | Firm | Date |
|---|---|---|
| Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301) in Patients With Severe Traumatic Brain Injury (TBI). (NCT06253923) | SHINKEI Therapeutics, Inc | 2024-06-01 |
Track SHINKEI Therapeutics, Inc automatically
Every clearance here is in the API, with alerts when new ones post.